Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

被引：0
|
作者：
Khouri, Issa F. [1 ]
Saliba, Rima M. [1 ]
Ledesma, Celina [1 ]
Jabbour, Elias J. [2 ]
Turturro, Francesco [3 ]
Alatrash, Gheath [4 ]
Ahmed, Sairah [1 ]
Oran, Betul [1 ]
Patel, Krina K. [1 ]
Olson, Amanda [4 ]
Marin, David [1 ]
Popat, Uday R. [1 ]
Suki, Tina S. [1 ]
Jorgensen, Jeffrey L. [5 ]
Medeiros, L. Jeffrey [5 ]
Gulbis, Alison M. [6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    De Vos, Sven
    Furman, Richard R.
    Barrientos, Jacqueline C.
    Wagner-Johnston, Nina D.
    Flinn, Ian
    Sharman, Jeff P.
    Boyd, Thomas
    Leonard, John P.
    Dansey, Roger
    Kim, Yeonhee
    Holes, Leanne M.
    Dubowy, Ronald L.
    Coutre, Steven E.
    BLOOD, 2013, 122 (21)
  • [32] Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)
    Hill, Brian T.
    Caimi, Paolo
    Kindwall-Keller, Tammy
    Habecker, Becky
    Kalaycio, Matt
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (02) : 297 - 299
  • [33] Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barrientos, Jacqueline C.
    Coutre, Steven E.
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Flinn, Ian W.
    Sharman, Jeff P.
    Schreeder, Marshall T.
    Boyd, Thomas E.
    Rai, Kanti R.
    Leonard, John P.
    Kim, Yeonhee
    Viggiano, Anthony
    Jahn, Thomas M.
    Furman, Richard R.
    BLOOD, 2014, 124 (21)
  • [34] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
    Welslau, M.
    Ghia, P.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Kozak, T.
    Simkovic, M.
    Kaplan, P.
    Kraychok, I
    Illes, A.
    de la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Lee, J. H.
    Wang, D.
    Patel, P.
    Quah, C.
    Jurczak, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 71 - 72
  • [35] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
    Jacob, Abraham
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 141 - 142
  • [36] Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier
    Keating, Michael J.
    Ferrajoli, Alessandra
    Lerner, Susan
    Wang, Xuemei
    O'Brien, Susan
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E35 - E35
  • [37] ANALYSIS OF TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Sallum, R.
    Dorman, E.
    Xu, Y.
    Tran-Kerr, K.
    O'Donnell, M.
    Sorensen, S.
    Szatkowski, A.
    Sengupta, N.
    Gaudig, M.
    VALUE IN HEALTH, 2014, 17 (07) : A616 - A616
  • [38] The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients.
    Byrd, JC
    Rai, KR
    Peterson, BL
    Appelbaum, FR
    Morrison, VA
    Kolitz, JE
    Shepherd, L
    Hines, JD
    Schiffer, CA
    Larson, RA
    BLOOD, 2003, 102 (11) : 73A - 73A
  • [39] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Keating, Michael J.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Sargent, Rachel L.
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    BLOOD, 2011, 118 (21) : 448 - 448
  • [40] Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    Ferrajoli, Alessandra
    Badoux, Xavier C.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lee, Bang-Ning
    Reuben, James M.
    Kantarjian, Hagop
    Keating, Michael
    BLOOD, 2009, 114 (22) : 89 - 90
12345